How Should Clinical AI Be Paid For? 3 Takeaways

Introduction: Clinical AI’s Financial Puzzle

As artificial intelligence solidifies its role in everyday clinical practice—not just as a tool for research, but as a direct contributor to patient care—the question of how health systems should pay for these technologies has become one of the thorniest unsolved issues in healthcare. While AI-powered diagnostics, predictive analytics, and care optimization tools promise profound improvements, they also challenge legacy payment models that were never designed for dynamic, software-driven interventions. The Peterson Health Technology Institute’s latest report shines a spotlight on this gap, warning both payers and providers of rising costs and calling the sector to action for more nuanced and adaptive reimbursement models.

Background: The Rise of Clinical AI and Payment Friction

Over the last decade, clinical AI has moved from proof-of-concept pilots to enterprise-wide adoption. Algorithms once tested in academic settings now make real-time decisions in radiology, pathology, population health, cardiology, intensive care, and beyond. Yet, the growth of AI has outpaced the evolution of healthcare financial systems and regulations. Traditional fee-for-service (FFS) structures struggle to accommodate the distinct value and intangible nature of software-driven care.

Conventional payments for medical technology are often tied to physical goods or discrete, time-limited interventions—surgical procedures, imaging studies, or medical devices. AI, by contrast, is continuously updated, refined, and integrated into care in ways that create recurring costs and unclear attribution of value. This complexity muddies the question of who should pay, how much, and for what clinical benefit.

Takeaway 1: Current Payment Models Are a Poor Fit for Clinical AI

The report’s first and perhaps starkest conclusion is that today’s prevailing healthcare payment models are, at best, awkward fits for clinical AI—and, at worst, outright barriers to its sensible deployment.

Fee-for-service: AI tools that assist in diagnostics or streamline workflow often exist as background infrastructure; they don’t map easily onto existing FFS billing codes. Providers struggle to capture their added value, and insurers find it difficult to assess whether a reimbursed “AI service” leads to improved outcomes or simply adds a layer of administrative cost.

Bundled payments: When clinical AI is incorporated within broader bundled payments or episode-based care models, its cost can be diffused across multiple services, diluting incentives for targeted adoption and long-term investment in high-performing algorithms.

Subscription and licensing models: Enterprise AI vendors often license software to health systems for annual or usage-based fees, but these expenditures are not always recognized in payer contracts. The result is a patchwork of local business agreements that create inconsistency and unpredictability in adoption.

Takeaway 2: Suboptimal Models Could Drive Healthcare Costs Higher

A key warning in the Peterson report is that without new frameworks, the convergence of clinical AI and poorly-suited payment structures could lead to an unchecked rise in costs. The risk is twofold:

• Overutilization: When payments are poorly calibrated, there is a risk that AI tools—designed to automate or augment clinical work—may be deployed not for their unique capabilities, but simply to bill additional or duplicative services.
• Waste and inefficiency: If AI’s clinical value is not well-defined in payment contracts, hospitals may license multiple competing solutions or integrate tools with marginal benefit, increasing costs without commensurate improvements in outcomes.
• Innovation bottlenecks: Inconsistent payment models can chill investment, causing promising AI companies to stagnate amid uncertainty over how, when, or if their products will generate sustainable revenue.

The Peterson Institute’s analysis draws parallels to past cycles in healthcare spending, warning that AI could repeat the same mistakes seen when past technologies were bolted onto outdated reimbursement models.

Takeaway 3: A Call for Smarter, Value-Driven Payment Approaches

To avoid these pitfalls, the report recommends purposeful redesign of healthcare payment models to reflect the unique attributes of AI. Among its recommendations:

• Evidence-based reimbursement: Prioritize payment structures that reward AI tools with clear, quantifiable clinical benefit, similar to how value-based care models reward efficacy and efficiency.
• Outcome-focused contracts: Rather than rigid, service-based reimbursement, adopt models in which payment depends on measurable improvements in patient outcomes, operational efficiency, or cost savings.
• Transparent evaluation mechanisms: Encourage the development and use of robust frameworks for evaluating the clinical impact and cost-effectiveness of AI, enabling more data-driven investment and payment decisions.

The report’s recommendations are designed to align incentives—from technology developers to payers to frontline clinicians—so that clinical AI is deployed thoughtfully, avoiding both cost overruns and underused innovation.

The Road Ahead: Navigating Uncertainty

Despite the challenges outlined above, there is broad consensus among healthcare leaders that AI will remain a key driver of transformation in clinical medicine for years to come. The central challenge, as illuminated by the Peterson Institute report, is not whether AI will be used, but how it will be paid for in a manner that rewards genuine value and patient benefit.

Health systems are now at a crossroads. Will they adapt payment models to reflect the new reality of software-driven healthcare, or will they allow outmoded structures to dictate the pace and shape of innovation? The choices made in the coming years will determine not only how much clinical AI costs, but how, and whether, it delivers its full promise for patients and providers alike.

(Source: MedCity News)